PreferredStockChannel
Dyne Therapeutics Inc | 5.375% Series A Mandatory Convertible Preferred Stock (DYN.PRA)

Prospectus excerpt:  Dividends on our Mandatory Convertible Preferred Stock will be payable on a cumulative basis when, as and if declared by our board of directors, at an annual rate of 5.375% on the liquidation preference of $100.00 per share. We may pay declared dividends in cash or, subject to certain limitations, in shares of common stock or by delivery of any combination of cash and shares of common stock on February 1, May 1, August 1 and November 1 of each year, commencing on February 1, 2015, and to, and including, November 1, 2017.

Full Prospectus PDF », DYN Page »

Series:A
Alternate symbology:DYN-A, DYN-PA, DYNprA
Redeemable?:Yes
Maturity Date:11/1/2017
Cumulative?:Yes
Conversion Ratio:2.5806 and 3.2258
Conversion Price:31 to $38.75
Shares Offered:4,000,000
Overallotment:600,000
Liquidation Preference:$100
Original Coupon:5.38%
Pay Period:Quarterly
Pay Dates:1-Feb, 1-May, 1-Aug, 1-Nov
CDx3 Compliance Rating: Learn DYN.PRA's Rating
Dyne Therapeutics is a muscle disease company focused on developing therapeutics for people living with genetically driven diseases. Co. is developing the following product candidates: DYNE-101, to address the genetic basis of myotonic dystrophy type 1 by targeting the toxic nuclear DMPK RNA that causes the disease; DYNE-251 for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exon 53, 45 and 44; and DYNE-301 to address the genetic basis of facioscapulohumeral dystrophy by reducing DUX4 expression in muscle tissue.

Preferred: DYN.PRA


Open the DYN Information Page »
Name: 
Dyne Therapeutics Inc
Website: 
www.dyne-tx.com
Sector: 
Biotechnology
Number of ETFs Holding DYN: 
18 (see which ones)
Total Market Value Held by ETFs: 
$32,396,111.9
Total Market Capitalization: 
$642,000,000
% of Market Cap. Held by ETFs: 
5.05%

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Dyne Therapeutics Inc | 5.375% Series A Mandatory Convertible Preferred Stock (DYN.PRA) Information Page | Preferred Stock Channel | www.PreferredStockChannel.com

Copyright © 2010 - 2022, All Rights Reserved Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.